Anzeige
Mehr »
Login
Dienstag, 16.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Im Fokus der Anleger: InnoCan Pharma vor entscheidendem Meilenstein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N6DV | ISIN: US30234E1047 | Ticker-Symbol:
NASDAQ
15.04.24
21:59 Uhr
0,550 US-Dollar
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
EYENOVIA INC Chart 1 Jahr
5-Tage-Chart
EYENOVIA INC 5-Tage-Chart

Aktuelle News zur EYENOVIA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.04.Eyenovia (EYEN) Down 18% on Disappointing Corporate Update4
08.04.EYENOVIA, INC. - 8-K, Current Report1
08.04.Eyenovia, Inc.: Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities61Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024 and a potential NDA to the FDA in 2025Continuing...
► Artikel lesen
03.04.Eyenovia, Inc.: Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings2
19.03.EYENOVIA, INC. - 8-K, Current Report2
18.03.Eyenovia Inc reports results for the quarter ended in December - Earnings Summary1
18.03.Recap: Eyenovia Q4 Earnings3
18.03.Eyenovia GAAP EPS of -$0.18 misses by $0.01, revenue of $2.58M beats by $2.46M2
18.03.EYENOVIA, INC. - 10-K, Annual Report1
18.03.Eyenovia, Inc.: Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update154Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery Reacquired development and commercialization rights to...
► Artikel lesen
13.03.Eyenovia, Inc.: NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals1
11.03.Eyenovia, Inc.: Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th2
05.03.Eyenovia falls despite FDA nod for pain therapy9
05.03.After Formosa snags FDA nod for reformulation of old steroid, partner Eyenovia plots launch6
05.03.Eyenovia, Formosa Gets FDA Approval For Clobetasol Propionate Ophthalmic Eye Drops3
05.03.US FDA approves Eyenovia's eye drug, Formosa Pharma says7
29.02.Upcoming FDA decision: Eyenovia's (EYEN) APP130075
13.02.FDA approves Eyenovia manufacturing facility in Redwood City4
13.02.Eyenovia passes FDA inspection for Mydcombi production5
13.02.Eyenovia, Inc.: Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility363Redwood City, California to complement Eyenovia's facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi NEW YORK, Feb....
► Artikel lesen
Seite:  Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1